Proteostasis Therapeutics
Innovative CFTR modulators for cystic fibrosis treatment through advanced ex vivo screening and clinical trials.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| USD | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (60 %) | 150 % | (80 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | (1160 %) | (3050 %) | (1180 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | (1180 %) | (3050 %) | (1180 %) | (7200 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | 880 % | 2255 % | 924 % | - |
Source: Company filings or news article
Related Content
Proteostasis Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for cystic fibrosis (CF), a genetic disease that primarily affects the lungs and other organs. The company operates in the healthcare and pharmaceutical market, targeting patients with CF, particularly those with the F508del mutation. Proteostasis employs a business model centered around research and development, advancing its proprietary CFTR modulators through clinical trials. The company generates revenue through partnerships, grants, and potential future sales of its investigational drugs. Proteostasis is currently conducting the CHOICES trial, utilizing ex vivo screening of patient-derived organoids to identify responsive patients. Their triple combination therapy includes posenacaftor (a corrector), dirocaftor (a potentiator), and nesolicaftor (an amplifier), showing promising results in Phase 2 trials. The company aims to further develop and commercialize these therapies to improve the quality of life for CF patients.
Keywords: cystic fibrosis, CFTR modulators, F508del mutation, ex vivo screening, clinical trials, biotechnology, posenacaftor, dirocaftor, nesolicaftor, healthcare.